3i Bioscience Investment Trust

International Biotechnology Trust (IBT), originally established as the 3i Bioscience Investment Trust, is a prominent London-listed investment trust dedicated to the global biotechnology and healthcare sectors. The trust seeks to provide shareholders with long-term capital appreciation by investing in a diversified portfolio of high-growth companies, ranging from early-stage private ventures to large-cap public entities. Its investment strategy covers a broad spectrum of therapeutic areas, including oncology, rare diseases, and neurology, as well as medical technology and healthcare services. Managed by 3i Group until 2005 and subsequently by SV Health Managers, the trust's management was transitioned to Schroders in 2023. IBT remains a key vehicle for investors seeking exposure to innovation in drug discovery and life sciences through a professionally managed, diversified portfolio.